Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases. Its lead asset, COYA 302 (low-dose IL-2 plus CTLA4-Ig), is in a Phase 2 trial for ALS and has received FDA IND acceptance for FTD. The company also has COYA 303 (LD IL-2 plus GLP-1 RA) in preclinical development and an autologous Treg cell therapy program with completed Phase 1 and Phase 2a ALS studies.
expected 2026-12-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-107281 | EDGAR | 96K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-040782 | EDGAR | 83K words |
| 2024-03-19 | 2023-12-31 | 0000950170-24-033161 | EDGAR | 81K words |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010599 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-343481 | EDGAR | 20K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-276058 | EDGAR | 22K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-106934 | EDGAR | 21K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069824 | EDGAR | 19K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-121837 | EDGAR | 23K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095075 | EDGAR | 21K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057056 | EDGAR | 19K words |
| 2023-11-08 | 2023-09-30 | 0000950170-23-060718 | EDGAR | 19K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039354 | EDGAR | 19K words |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020076 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-15 | 0001193125-26-391378 | EDGAR | 1K words |
| 2026-08-11 | 0001193125-26-343473 | EDGAR | 3K words |
| 2026-04-02 | 0001193125-26-139094 | EDGAR | 4K words |
| 2026-03-16 | 0001193125-26-107276 | EDGAR | 3K words |
| 2026-01-30 | 0001193125-26-030531 | EDGAR | 1K words |
| 2026-01-20 | 0001193125-26-016017 | EDGAR | 0K words |
| 2026-01-08 | 0001193125-26-007042 | EDGAR | 1K words |
| 2025-12-17 | 0001193125-25-321737 | EDGAR | 1K words |
| 2025-11-12 | 0001193125-25-276022 | EDGAR | 3K words |
| 2025-10-27 | 0001193125-25-250709 | EDGAR | 1K words |
79 total filings indexed. 55 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001835022 |
| Ticker | COYA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.coyatherapeutics.com |
| Listed | 2022-12-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/COYA (~200 tokens, structured JSON with cryptographic provenance)